NCT02979977 2026-02-04
Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
Yale University
Phase 2 Completed
Clinical Trials
3 trialsNCT01856478 2026-01-12
LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
Boehringer Ingelheim
Phase 3 Completed
NCT06494189 2025-12-29
Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma
West China Hospital
Phase 1 Completed